In the present study, we evaluated the therapeutic potential of donepezil, a reversible acetylcholinesterase inhibitor approved by the FDA (Bryson and Benfield, 1997), in four children affected by GoF variants of KCNQ2 and KCNQ3 encephalopathy. Here, KCNQ3 is linked to Encephalopathy.